Stockreport

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

GENFIT S.A. - American Depositary Shares  (GNFT) 
PDF EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pen [Read more]